Pharsight

Jevtana Kit is owned by Sanofi Aventis Us.

Jevtana Kit contains Cabazitaxel.

Jevtana Kit has a total of 6 drug patents out of which 0 drug patents have expired.

Jevtana Kit was authorised for market use on 17 June, 2010.

Jevtana Kit is available in solution;intravenous dosage forms.

Jevtana Kit can be used as increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering 20 to 25 mg/m2 cabazitaxel after a premedication regimen that includes an h2-antagonist, increasing survival in mcrpc patients previously treated with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone after a premedication regimen that includes an antihistamine, a corticosteroid, and an h2-antagonist, increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlorpheniramine, 8 mg dexamethasone, and an h2-agonist.

The generics of Jevtana Kit are possible to be released after 27 April, 2031.

Application	Filing Date	Opposition Party	Legal Status
EP10782039A	2021-12-10	Maiwald Patent- und Rechtsanwaltsgesellschaft mbH	Granted and Under Opposition
EP10782039A	2021-12-09	STADA Arzneimittel AG	Granted and Under Opposition
EP10782039A	2021-12-03	Vossius & Partner Patentanwälte Rechtsanwälte mbB	Granted and Under Opposition
EP10782039A	2021-06-08	Generics (U.K.) Limited	Granted and Under Opposition
EP10782039A	2021-03-31	Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH	Granted and Under Opposition
EP10782039A	2021-03-23	Fresenius Kabi Deutschland GmbH	Granted and Under Opposition
EP10782039A	2021-03-22	medac Gesellschaft für klinische Spezialpräparate mbH	Granted and Under Opposition
EP10782039A	2021-03-12	EVER Valinject GmbH	Granted and Under Opposition
EP10782039A	2021-03-12	Zentiva k.s.	Granted and Under Opposition
EP10782039A	2021-03-10	Glenmark Pharmaceuticals Europe Ltd	Granted and Under Opposition
EP10782039A	2021-03-10	Accord Healthcare Ltd	Granted and Under Opposition
EP10782039A	2021-03-10	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP04787385A	2013-10-14	STADA Arzneimittel AG	Opposition rejected

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US8927592	March, 2016	FWD Entered	AVENTIS PHARMA S.A.	Mylan Laboratories Limited

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7241907	SANOFI AVENTIS US	Acetone solvate of dimethoxy docetaxel and its process of preparation	Dec, 2025 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7241907 (Pediatric)	SANOFI AVENTIS US	Acetone solvate of dimethoxy docetaxel and its process of preparation	Jun, 2026 (3 years from now)
US10583110	SANOFI AVENTIS US	Antitumoral use of cabazitaxel	Oct, 2030 (7 years from now)
US10716777	SANOFI AVENTIS US	Antitumoral use of cabazitaxel	Oct, 2030 (7 years from now)
US8927592	SANOFI AVENTIS US	Antitumoral use of cabazitaxel	Oct, 2030 (7 years from now)
US8927592 (Pediatric)	SANOFI AVENTIS US	Antitumoral use of cabazitaxel	Apr, 2031 (7 years from now)

Do you want to check out JEVTANA KIT patents from before 2022?

Exclusivity	Exclusivity Expiration
M (M)	Dec 18, 2023

Drugs and Companies using CABAZITAXEL ingredient

Market Authorisation Date: 17 June, 2010

Treatment: Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlorpheniramine, 8 mg de...

Dosage: SOLUTION;INTRAVENOUS